| Not Yet Recruiting | Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD NCT07393685 | Tianjin Medical University | — |
| Completed | Analysis of Single Respiratory Viral Infections Versus Co-infections: Prevalence and ICU Needs in Hospitalized NCT06779175 | Kocaeli University | — |
| Active Not Recruiting | Evaluating the Human Immune Response to the JYNNEOS Vaccine NCT06366672 | Washington University School of Medicine | EARLY_Phase 1 |
| Completed | RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection NCT06149494 | Altesa Biosciences, Inc. | Phase 2 |
| Active Not Recruiting | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) NCT05797246 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vacc NCT05875961 | Seqirus | Phase 1 |
| Completed | Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and NCT05874713 | Seqirus | Phase 2 |
| Unknown | Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects NCT05619770 | 101 Therapeutics | Phase 1 |
| Completed | Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Sa NCT05284097 | London School of Hygiene and Tropical Medicine | Phase 2 |
| Completed | Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 D NCT06113757 | AVB Biotechnology | N/A |
| Completed | A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine i NCT05422326 | Seqirus | Phase 2 |
| Completed | Post-COVID-19 Monitoring in Routine Health Insurance Data With Focus on Autoimmune Diseases (POINTED-AD) NCT05606198 | Technische Universität Dresden | — |
| Completed | Tobacco Use and the Risk of COVID-19 and Adverse Outcomes NCT05321433 | Karolinska Institutet | — |
| Unknown | STS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care NCT05277285 | Hellenic Institute for the Study of Sepsis | Phase 2 |
| Unknown | Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory NCT05376124 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Completed | Post-COVID-19 Monitoring in Routine Health Insurance Data NCT05074953 | Technische Universität Dresden | — |
| Completed | Universal Anti-Viral Vaccine for Healthy Elderly Adults NCT04441047 | Mirror Biologics, Inc. | Phase 1 / Phase 2 |
| Completed | EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19 NCT04822818 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men NCT04772469 | University of California, San Francisco | N/A |
| Completed | Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 ( NCT04710199 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 2 |
| Completed | A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults NCT04758962 | GlaxoSmithKline | Phase 1 |
| Completed | Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes NCT04769167 | Washington University School of Medicine | N/A |
| Completed | A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety NCT04644484 | Synermore Biologics (Suzhou) Co., Ltd. | Phase 3 |
| Completed | Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 NCT04476979 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Terminated | Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19) NCT04382131 | University of Edinburgh | N/A |
| Completed | Bacillus Calmette-guérin Vaccination to Prevent COVID-19 NCT04414267 | Hellenic Institute for the Study of Sepsis | Phase 4 |
| Completed | Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19 NCT04412551 | Dalarna County Council, Sweden | — |
| Unknown | SARS-CoV 2 in Personal Protective Equipment NCT04398043 | Hospital de Clinicas José de San Martín | — |
| Completed | Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early NCT04398004 | Hellenic Institute for the Study of Sepsis | Phase 2 |
| Completed | ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Ca NCT04367740 | University of North Carolina, Chapel Hill | — |
| Completed | CoVid-19 - Infection and Antibody Formation in the Viennese Population NCT04346264 | Ludwig Boltzmann Institute for Lung Health | — |
| Completed | A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocom NCT04380701 | BioNTech SE | Phase 1 / Phase 2 |
| Recruiting | Convalescent Plasma Collection and Treatment in Pediatrics and Adults NCT04376034 | West Virginia University | Phase 3 |
| Completed | suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 ( NCT04357366 | Hellenic Institute for the Study of Sepsis | Phase 2 |
| Terminated | Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19 NCT04322396 | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Phase 2 |
| Completed | Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction NCT04339712 | Hellenic Institute for the Study of Sepsis | Phase 2 |
| Enrolling By Invitation | LázBarát™ (FeverFriend™) Projekt: Attitude Toward Fever and Its Change in the Healthcare System NCT04633603 | University of Pecs | — |
| Withdrawn | Modelling the Interaction Between Synthetic Model Immunogens and the Induced B and T Cell Repertoires. NCT04046978 | Imperial College London | N/A |
| Completed | Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects NCT04074928 | Seqirus | Phase 3 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Va NCT04062669 | GlaxoSmithKline | Phase 1 |
| Active Not Recruiting | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma NCT04124198 | Christian von Buchwald | N/A |
| Unknown | The Efficacy and Safety of Nucleos(t)Ide Analogues in the Treatment of HBV-related Acute-on-chronic Liver Fail NCT03640728 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Completed | Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly NCT03739112 | Medicago | Phase 3 |
| Unknown | Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine NCT03776994 | SRI International | Phase 1 |
| Completed | Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2 NCT03392207 | Butantan Institute | — |
| Completed | Cantharidin and Occlusion in Verruca Epithelium NCT03487549 | Verrica Pharmaceuticals Inc. | Phase 2 |
| Withdrawn | A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vacc NCT03192371 | GlaxoSmithKline | Phase 4 |
| Completed | The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After On NCT03294135 | GlaxoSmithKline | Phase 4 |
| Completed | Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adult NCT03321968 | Medicago | Phase 3 |
| Completed | Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vac NCT03301051 | Medicago | Phase 3 |
| Completed | VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents NCT03110770 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Terminated | Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Ad NCT02927431 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chic NCT02991872 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adul NCT02831751 | Medicago | Phase 2 |
| Completed | Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults NCT02768805 | Medicago | Phase 2 |
| Terminated | Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixe NCT02613403 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ- NCT02593851 | Janssen Sciences Ireland UC | Phase 1 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children NCT02548078 | GlaxoSmithKline | Phase 2 |
| Completed | A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell R NCT02545517 | GlaxoSmithKline | Phase 3 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults NCT02485301 | GlaxoSmithKline | Phase 2 |
| Completed | Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza NCT02469298 | GlaxoSmithKline | Phase 2 |
| Completed | Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection NCT03119025 | Russian Academy of Medical Sciences | Phase 1 / Phase 2 |
| Completed | Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza NCT02233816 | Medicago | Phase 2 |
| Completed | Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the NCT02236052 | Medicago | Phase 2 |
| Completed | Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years NCT02012998 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adul NCT02022163 | Medicago | Phase 1 |
| Completed | Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults NCT01991587 | Medicago | Phase 1 / Phase 2 |
| Completed | Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine. NCT01991561 | Medicago | Phase 2 |
| Completed | Replacement of Lamivudine by Telbivudine to Improve Renal Function NCT02447705 | Chang Gung Memorial Hospital | Phase 2 / Phase 3 |
| Completed | Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) NCT01839188 | MCM Vaccines B.V. | Phase 3 |
| Completed | Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in H NCT01839175 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | DNA-based Influenza Vaccine in the Elderly NCT01587131 | University of Manitoba | Phase 1 |
| Completed | Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) NCT01553279 | MCM Vaccines B.V. | Phase 3 |
| Completed | Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne NCT01562444 | GlaxoSmithKline | Phase 4 |
| Completed | Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V NCT01480258 | MCM Vaccines B.V. | Phase 3 |
| Unknown | Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplan NCT01289301 | Hannover Medical School | Phase 4 |
| Completed | Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419- NCT01341639 | MCM Vaccines B.V. | Phase 3 |
| Completed | A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) NCT01340937 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) NCT01337167 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, NCT02630082 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine NCT01244867 | Medicago | Phase 2 |
| Completed | Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults NCT00853255 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Withdrawn | Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients NCT01062659 | University of Ulm | — |
| Completed | Clinic-based ART Diagnostic Evaluation NCT01791556 | Walter Reed Army Institute of Research (WRAIR) | N/A |
| Completed | Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Inf NCT01021397 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young A NCT00980447 | UMN Pharma Inc. | Phase 2 |
| Unknown | Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients NCT01055990 | Shanghai Public Health Clinical Center | Phase 2 |
| Completed | Safety of H1N1 Influenza Vaccination in Pregnant Women NCT01842997 | Jiangsu Province Centers for Disease Control and Prevention | Phase 4 |
| Completed | Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults NCT00984945 | Medicago | Phase 1 |
| Completed | Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults NCT00921726 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Avian Influenza Studies In Lebanon NCT01107262 | St. Jude Children's Research Hospital | — |
| Completed | Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older NCT00975572 | Jiangsu Province Centers for Disease Control and Prevention | Phase 2 |
| Completed | Epidemiological Study in Children and Adolescents With Chronic Hepatitis B NCT01163240 | Novartis Pharmaceuticals | — |
| Completed | Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles NCT00921934 | Pascoe Pharmazeutische Praeparate GmbH | — |
| Unknown | A Single-Arm Study Evaluating the Efficacy of Liquid Acupuncture Therapeutics in Chronic Hepatitis B NCT00815464 | Yu Medical Garden | N/A |
| Completed | A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen NCT00749580 | University of South Florida | N/A |
| Completed | Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine NCT00734175 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine NCT00641017 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults NCT00516035 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults NCT00488046 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Viral Infections in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations NCT00448604 | University Hospital, Geneva | — |
| Completed | Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Childr NCT00366782 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B) NCT00380237 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants NCT00308412 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults NCT00347672 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Pharmacokinetic Study Of Valaciclovir Hydrochloride Tablets NCT00343278 | GlaxoSmithKline | Phase 4 |
| Completed | Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A) NCT00110279 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Pilot Safety Study to Determine the Ability of the Protector Cap Jet Injector to Prevent Cross-Contamination NCT00219453 | PATH | Phase 1 |
| Completed | Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C NCT00948220 | University of Ulm | Phase 4 |
| Completed | Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers NCT00001164 | National Cancer Institute (NCI) | — |
| Completed | Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine NCT00722774 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |